Endometrial cancer+1
Not recruitingStudy of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy
Study of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy
- Disease:Endometrial cancerCervix carcinoma
- Substances:CarboplatinPaclitaxel+2
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Netris Pharma











